AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 15.6%. OMCL and Masimo Corporation MASI.ĪMN Healthcare, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 1.1%. Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. The Zacks Consensus Estimate for the company’s third-quarter fiscal 2022 revenues is pegged at $25.5 million, suggesting a 6.7% improvement from the year-ago reported number. In the past 90 days, the Zacks Consensus Estimate for its earnings has widened from a loss of $1.10 to $1.15 per share. Surmodics is witnessing a negative estimate revision trend for 2022. The amount of revenues the company derives from such arrangements depend upon its ability or its licensees’ ability to successfully develop, obtain regulatory approval for, manufacture (if applicable), market and sell products incorporating Surmodics’ technologies. Reliance on Third Parties: A principal element of Surmodics’ business strategy is to enter into licensing arrangements with medical device and other companies that manufacture products incorporating its technologies. Changes in existing regulations or adoption of new governmental regulations or policies could prevent or delay regulatory approval of products incorporating Surmodics’ technologies or subject the same to additional regulation. Any failure to comply with these legal and regulatory requirements could impact the company’s business. Regulatory Headwinds: Surmodics’ products and business activities are subject to a complex set of regulations, both in the United States and internationally. Strong potential in the company’s Sublime Radial Access device and Pounce Arterial Thrombectomy platform raise our optimism about the stock. Surmodics confirmed making crucial progress on its SurVeil drug-coated balloon premarket approval submission. The company registered robust revenues from its IVD segment, as well as from its Product sales. Strong Q2 Results: Surmodics’ solid second-quarter fiscal 2022 results buoy optimism about the stock. Additionally, the data showed that no adjunctive thrombectomy devices were required to remove clots and 95% of these procedures could be performed while avoiding the use of thrombolytics within the target lesion. In April, Surmodics announced that its Pounce Thrombectomy System achieved 100% technical success in 20 FIH procedures.
Thrombectomy Prospects Bright: Surmodics’ aim to leverage its proprietary Pounce thrombectomy platform technology to develop products raises our optimism. The company is looking forward to submitting these data in a late-breaking clinical trial presentation at a conference in the coming months. It also mentioned that physicians and the steering committee were satisfied with both the analyses and the clinical results. During the second-quarter fiscal 2022 earnings call in April, Surmodics confirmed the completion of these analyses. During the first-quarter fiscal 2022 earnings call, Surmodics stated that the Physician Steering Committee for the company's SWING first-in-human (“FIH”) clinical trial had advised the latter to conduct additional analyses of the clinical data. Efforts to Boost R&D: We are optimistic about Surmodics’ solid efforts to improve its R&D stature, which has been a key growth driver.
0 kommentar(er)
